Ipamorelin is a selective GHRP acting on the ghrelin receptor. Tesamorelin is a GHRH analogue acting on the GHRH receptor. They stimulate GH release through entirely different pathways — making them highly complementary rather than competing alternatives.
| Category | Ipamorelin | Tesamorelin |
|---|---|---|
| Compound Class | GHRP (Growth Hormone Releasing Peptide) | GHRH Analogue (Growth Hormone Releasing Hormone) |
| Receptor Target | Ghrelin receptor (GHSR-1a) | GHRH receptor (pituitary somatotrophs) |
| Primary Mechanism | Ghrelin receptor agonism → pulsatile GH release | GHRH receptor agonism → pulsatile GH release + IGF-1 |
| Visceral Fat Loss | Moderate — via GH-mediated lipolysis | Excellent — FDA-approved for lipodystrophy; Phase 3 data |
| Muscle Preservation | Good — GH pulse supports lean mass retention | Good — IGF-1 elevation supports anabolism |
| Cortisol Effect | Minimal — highly selective GHRP | Minimal — GHRH analogue; no direct cortisol effect |
| Prolactin Effect | Minimal — key differentiator from GHRP-2/6 | Minimal |
| Cognitive Benefits | Limited data | Phase 2 data showing memory and executive function improvement in adults 60+ |
| Liver Fat (NAFLD) | Limited data | Positive data — reduces hepatic fat in metabolic syndrome |
| Typical Dose | 100–300 mcg, 2–3× daily | 1–2 mg once daily (morning) |
| Half-Life | ~2 hours | ~26 minutes (but pulsatile GH effect lasts 2–3 hours) |
| Administration | SubQ injection | SubQ injection |
| Evidence Level | Extensive preclinical; limited human data | Phase 2/3 human trials; FDA-approved (Egrifta) |
| Stackable With | CJC-1295, Tesamorelin, Sermorelin, BPC-157 | Ipamorelin, CJC-1295, BPC-157, NAD+ |
| Research Goal | Recommended | Reason |
|---|---|---|
| Visceral / abdominal fat reduction | Tesamorelin | FDA-approved for lipodystrophy; strongest evidence for visceral fat |
| GH pulse amplification (max output) | Stack both | GHRH + GHRP dual-pathway produces larger pulse than either alone |
| Minimal cortisol / prolactin elevation | Ipamorelin | Most selective GHRP; no significant cortisol or prolactin effect |
| Cognitive function (adults 60+) | Tesamorelin | Phase 2 data on memory and executive function |
| Liver fat / NAFLD improvement | Tesamorelin | Reduces hepatic fat in metabolic syndrome research |
| Muscle preservation / anti-catabolism | Stack both | Combined GH + IGF-1 elevation maximizes lean mass support |
| Sleep quality / recovery | Ipamorelin | GH pulse timing with evening dosing supports deep sleep stages |
| Long-term protocol (12+ weeks) | Ipamorelin | Highly selective; favorable long-term safety profile |
| Metabolic syndrome / insulin sensitivity | Tesamorelin | Visceral fat reduction improves insulin sensitivity downstream |
Ipamorelin is a selective GHRP (growth hormone releasing peptide) that stimulates GH release by activating the ghrelin receptor (GHSR-1a) in the pituitary. Tesamorelin is a GHRH analogue — a synthetic version of growth hormone releasing hormone — that stimulates GH release through the GHRH receptor. They work through entirely different receptors and are highly complementary when stacked.
Tesamorelin has the stronger evidence base for fat loss, particularly visceral (abdominal) fat. It is FDA-approved for HIV-associated lipodystrophy and has multiple Phase 3 trials demonstrating significant visceral fat reduction. Ipamorelin also supports fat loss through GH pulse amplification but is not specifically studied for visceral fat reduction. For targeted abdominal fat loss, Tesamorelin is the more evidence-backed choice.
Yes — Ipamorelin and Tesamorelin are highly complementary. Tesamorelin acts on the GHRH receptor while Ipamorelin acts on the ghrelin receptor (GHSR-1a). Using both simultaneously produces a larger GH pulse than either alone because they stimulate GH release through independent pathways. This is the same principle as the CJC-1295 + Ipamorelin stack, with Tesamorelin substituted for CJC-1295.
Tesamorelin is used in research for visceral fat reduction, metabolic syndrome, HIV-associated lipodystrophy, and cognitive function in older adults. It is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy. Research also shows benefits for liver fat (NAFLD), insulin sensitivity, and cognitive performance in adults over 60.
Ipamorelin is used in research for GH pulse amplification, muscle preservation, fat loss, sleep quality improvement, and anti-aging protocols. It is highly selective for GH release with minimal effect on cortisol or prolactin — a key differentiator from older GHRPs like GHRP-2 and GHRP-6. It is most commonly stacked with CJC-1295 or Tesamorelin to amplify the combined GH pulse.
No — Ipamorelin is notable for its high selectivity. Unlike GHRP-2 and GHRP-6, Ipamorelin does not significantly increase cortisol, prolactin, or ACTH at research doses. This selectivity makes it the preferred GHRP for long-term protocols where cortisol elevation would be undesirable.
Tesamorelin is a synthetic analogue of endogenous GHRH (growth hormone releasing hormone) with a trans-3-hexenoic acid group attached to stabilize it against dipeptidyl peptidase IV (DPP-IV) degradation. It binds to the GHRH receptor on pituitary somatotrophs, stimulating pulsatile GH secretion. The resulting GH pulse then stimulates IGF-1 production in the liver, which drives downstream anabolic and lipolytic effects.
Choose Tesamorelin if your primary research goal is visceral fat reduction, metabolic improvement, or cognitive function in older adults — it has the strongest evidence for these endpoints. Choose Ipamorelin if your primary goal is GH pulse amplification with minimal cortisol/prolactin side effects, or if you are stacking with a GHRH analogue. For maximum GH output, stack both together.
Both compounds available from Purgo Labs — ≥99% purity, third-party COA on every batch. Use code HEALTH for 15% off.
Shop Purgo Labs — Use Code HEALTHMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.